Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: Dependence on phosphorothioate modification and reversal by heparin

Molecular Medicine

Volumn 2, Issue 4, 1996, Pages 429-438

  Hartmann, Gunther ^a   Krug, Anne ^a   Waller Fontaine, Kerstin ^a   Endres, Stefan ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; GLYCOPROTEIN; HEPARIN; LIPOPOLYSACCHARIDE; OLIGONUCLEOTIDE; PHOSPHOROTHIOIC ACID; TUMOR NECROSIS FACTOR;

ARTICLE; BINDING SITE; CELL SURFACE; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION;

EID: 0029771599     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03401902     Document Type: Article

References (42)

1. Askari FK, McDonnell WM. (1996) Antisense-oligonucleotide therapy. N. Engl. J. Med. 334: 316-318.
2. Sharma HW, Narayanan R. (1995) The therapeutic potential of antisense oligonucleotides. Bioessays 17: 1055-1063.
3. Stein CA, Narayanan R. (1994) Antisense oligodeoxynucleotides. Curr. Opin. Oncol. 6: 587-594.
4. Wagner RW. (1994) Gene inhibition using antisense oligodeoxynucleotides. Nature 372: 333-335.
5. Rossi JJ. (1995) Therapeutic antisense and ribozymes. Br. Med. Bull. 51: 217-225.
6. Kitajima I, Shinohara T, Bilakovics J, Brown DA, Xu X, Nerenberg M. (1992) Ablation of transplanted HTLV-I tax-transformed tumors in mice by antisense inhibition of NF-κB. Science 258: 1792-1795.
7. Higgins KA, Perez JR, Coleman TA, et al. (1993) Antisense inhibition of the p65 subunit of NF-κB blocks tumorigenicity and causes tumor regression. Proc. Natl. Acad. Sci. U.S.A. 90: 9901-9905.
8. Schwab G, Chavany C, Duroux I, et al. (1994) Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. Proc. Natl. Acad. Sci. U.S.A. 91: 10460-10464.
9. Skorski T, Nieborowska SM, Nicolaides NC, et al. (1994) Suppression of Philadelphia 1 leukemia cell growth in mice by bcr-abl antisense oligodeoxynucleotide. Proc. Natl. Acad. Sci. U.S.A. 91: 4504-4508.
10. Offensperger WB, Offensperger S, Walter E, et al. (1993) In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate-modified antisense oligodeoxynucleotides. EMBO J. 12: 1257-1262.
11. Morishita R, Gibbons GH, Ellison KE, et al. (1994) Intimai hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J. Clin. Invest. 93: 1458-1464.
12. Bayever E, Iversen PL, Bishop MR, et al. (1993) Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: Initial results of a phase I trial. Antisense Res. Dev. 3: 383-390.
13. Nichols GL. (1995) Antisense oligodeoxynucleotides as therapeutic agents for chronic myelogenous leukemia. Antisense Res. Dev. 5: 67-69.
14. Gewirtz AM. (1994) Treatment of chronic myelogenous leukemia (CML) with c-myb antisense oligodeoxynucleotides. Bone Marrow Transplant. 14: S57-S61.
15. Zhang R, Yan J, Shahinian H, et al. (1995) Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HTV-infected subjects. Clin. Pharmacol. Ther. 58: 44-53.
16. Cohen J. (1995) AIDS therapy. New hope against blindness. Science 268: 368-369.
17. Hawkins JW. (1995) Oligonucleotide therapeutics: Coming 'round the clubhouse turn. Antisense Res. Dev. 5: 1.
18. Gura T. (1995) Antisense has growing pains. Science 270: 575-577.
19. Stein CA. (1995) Does antisense exist? Nature Medicine 1: 1119-1121.
20. Jansen B, Wadl H, Inoue SA, et al. (1995) Phosphorothioate oligonucleotides reduce melanoma growth in a SCID-hu mouse model by a nonantisense mechanism. Antisense Res. Dev. 5: 271-277.
21. Krieg AM, Yi AK, Matson S, et al. (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546-549.
22. Chavany C, Connell Y, Neckers L. (1995) Contribution of sequence and phosphorothioate content to inhibition of cell growth and adhesion caused by c-myc antisense oligomers. Mol. Pharmacol. 48: 738-746.
23. Obrien SG, Kirkland MA, Melo JV, et al. (1994) Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines. Leukemia 8: 2156-2162.
24. Bøyum A. (1968) Isolation of mononuclear cells and granulocytes from human blood (paper IV). Scand. J. Clin. Lab. Invest. 21: 77-89, 107-109.
25. Endres S, Fülle HJ, Sinha B, et al. (1991) Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-α and interleukin-1β by human mononuclear cells. Immunology 72: 56-60.
26. Pennica D, Nedwin GE, Hayflick JS, et al. (1984) Human tumour necrosis factor: Precursor structure, expression and homology to lymphotoxin. Nature 312: 724-729.
27. Nedwin GE, Naylor SL, Sakaguchi AY, et al. (1985) Human lymphotoxin and tumor necrosis factor genes: Structure, homology and chromosomal localization. Nucleic Acids Res. 13: 6361-6373.
28. Breslauer KJ, Frank R, Blocker H, Markey LA. (1986) Predicting DNA duplex stability from the base sequence. Proc. Natl. Acad. Sci. U.S.A. 83: 3746-3750.
29. van der Meer JW, Endres S, Lonnemann G, et al. (1988) Concentrations of immunoreactive human tumor necrosis factor α produced by human mononuclear cells in vitro. J. Leukocyte Biol. 43: 216-223.
30. Perez JR, Li Y, Stein CA, Majumder S, van Oorschot A, Narayanan R. (1994) Sequence-independent induction of Sp1 transcription factor activity by phosphorothioate oligodeoxynucleotides. Proc. Natl. Acad. Sci. U.S.A. 91: 5957-5961.
31. Weidner DA, Valdez BC, Henning D, Greenberg S, Busch H. (1995) Phosphorothioate oligonucleotides bind in a non sequence-specific manner to the nucleolar protein c23/nucleolin. FEBS Lett. 366: 146-150.
32. Bergan RC, Kyle E, Connell Y, Neckers L. (1995) Inhibition of protein-tyrosine kinase activity in intact cells by the aptameric action of oligodeoxynucleotides. Antisense Res. Dev. 5: 33-38.
33. Chang NS, Intrieri C, Mattison J, Armand G. (1994) Synthetic polysulfated hyaluronic acid is a potent inhibitor for tumor necrosis factor production. J. Leukoc. Biol. 55: 778-784.
34. + T cells and macrophages. Immunology 78: 50-57.
35. Pacifici R, Basilico C, Roman J, Zutter MM, Santoro SA, McCracken R. (1992) Collagen-induced release of interleukin 1 from human blood mononuclear cells. Potentiation by fibronectin binding to the alpha 5 beta 1 integrin. J. Clin. Invest. 89: 61-67.
36. Dawes J. (1993) Interactions of heparins in the vascular environment. Haemostasis 1: 212-219.
37. Leung L, Saigo K, Grant D. (1989) Heparin binds to human monocytes and modulates their procoagulant activities and secretory phenotypes. Effects of histidine-rich glyco-protein. Blood 73: 177-184.
38. Stein CA, Cheng YC. (1993) Antisense oligonucleotides as therapeutic agents - Is the bullet really magical? Science 261: 1004-1012.
39. Schindler R, Clark BD, Dinarello CA. (1990) Dissociation between interleukin-1 beta mRNA and protein synthesis in human peripheral blood mononuclear cells. J. Biol. Chem. 265: 10232-10237.
40. Haskill S, Johnson C, Eierman D, Becker S, Warren K. (1988) Adherence induces selective mRNA expression of monocyte mediators and proto-oncogenes. J. Immunol. 140: 1690-1694.
41. Ekre HP, Naparstek Y, Lider O, et al. (1992) Anti-inflammatory effects of heparin and its derivatives: Inhibition of complement and of lymphocyte migration. Adv. Exp. Med. Biol. 313: 329-340.
42. Galbraith WM, Hobson WC, Giclas PC, Schlechter PJ, Agrawal S. (1994) Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Dev. 4: 201-206.